Each time I've requested pharmacogenomic testing, I have found a clinically sizeable variant within a gene that may impact my therapy options. In a substantial review population, the rate of clinically major variants in a minimum of just one test was above 90%.The most typical genes normal thought of linked to cancer chance are BRCA1 and BRAC2. The